Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Eli Lilly And Co (LLY) Price & Performance

First Citizens BancShares IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Eli Lilly And Co — how do they compare? First Citizens BancShares Inc trades at $2,170.41 (market cap $23.76B), while Eli Lilly And Co trades at $1,171.3 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 43.4× First Citizens BancShares Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.6%). Which is the better fit depends on your goals.

FCNCALLY
Market Cap
$23.76B$1.03T
Sector
Sector/ThematicHealth
52-Week High
$2.20K$1.24K
52-Week Low
$1.64K$625.65
Dividend Yield
0.41%0.6%
Enterprise Value
$1.07T

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,166.64, up 5.06% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a solid net income margin of 24.35%. Recent news includes a planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.

Outlook remains stable with consistent revenue near $9.3B and profit growth. Risks include margin pressure and credit trends, but analyst consensus is a $2,320 price target with a hold-heavy rating. The stock presents a value opportunity with a low P/E of 11.94, though investor sentiment is cautious amid sector challenges.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY